SCHEMBL5437713

SCHEMBL5437713

Nc1ccc2c(c1)c(Cl)nn2CC1CCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 5/20 0.40
▸ CNR2 P34972 4/20 0.40
▸ ACHE P22303 2/20 0.40
▸ GRM4 Q14833 1/20 0.38
▸ PADI4 Q9UM07 1/20 0.38
▸ KDM4C Q9H3R0 3/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ OPRD1 P41143 2/20 0.35
▸ OPRM1 P35372 1/20 0.35
▸ OPRK1 P41145 1/20 0.35
▸ GRM2 Q14416 3/20 0.35
▸ PDE4A P27815 1/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ PDE4C Q08493 1/20 0.34
▸ PDE4D Q08499 1/20 0.34
▸ PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5443607 0.94 KDM4C (0.39) CNR1CNR2ACHEGRM4PADI4
SCHEMBL5438052 0.79 CNR2 (0.52) CNR1CNR2ACHEMEN1MAPT
SCHEMBL27693955 0.78 OPRM1 (0.43) CNR1CNR2ACHEGRM4PADI4
SCHEMBL23467039 0.75 KDM4C (0.40) CNR1CNR2ACHEPADI4KDM4C
SCHEMBL6069757 0.75 CNR2 (0.54) CNR1CNR2ACHEKDM4CBCHE
SCHEMBL29770896 0.75 KDM4C (0.40) CNR1CNR2ACHEPADI4KDM4C
SCHEMBL5307216 0.73 CNR2 (0.48) CNR1CNR2ACHEKDM4CMEN1
SCHEMBL14360901 0.73 AR (0.45) CNR1GRM4KDM4CMAPTKMT2A
SCHEMBL5443599 0.73 GRM4 (0.40) CNR1CNR2ACHEGRM4KDM4C
SCHEMBL5464861 0.72 CNR1 (0.39) CNR1CNR2ACHEGRM4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101098857-A Nitro indazole derivatives ASTRAZENECA AB (SE) 2008-01-02 — — CN disclosed
US-20070265325-A1 Nitro Indazole Derivatives ASTRAZENECA AB (SE) 2007-11-15 — — US disclosed
US-20070265325-A1 Nitro Indazole Derivatives ASTRAZENECA AB (SE) 2007-11-15 — — US disclosed
US-20070265325-A1 Nitro Indazole Derivatives ASTRAZENECA AB (SE) 2007-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265325-A1 Nitro Indazole Derivatives NOS3, CYP3A43, NOS2 CNR1 155/4885CNR2 210/4885ACHE 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback